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Heart rate variability: measurement and emerging use in critical care medicine  43 
 44 
Introduction 45 
 46 
Stephen Hales in 1733 was the first to report that the time interval between individual 47 
arterial pulsations varied in horses.1 Since then, the introduction of ambulatory ECG has led 48 
to the recognition that the time period between successive R waves on the ECG varies in 49 
mammals.1, 2 This variability between heartbeats or R-R interval (RRi) is a feature of the 50 
healthy cardiovascular system and is more commonly known as the heart rate variability 51 
(HRV).2,3 52 
 53 
Hon and Lee first recognised the clinical potential of HRV when they noted that acute 54 
alterations in the HRV were a marker of foetal distress and predicted foetal hypoxia.4 Today, 55 
monitoring the variability of foetal heart rate has become a standard of care and has been 56 
responsible for significant reductions in foetal morbidity and mortality.5,4  Similar alterations 57 
in HRV have been recognised post myocardial infarction and are associated with a 5-fold 58 
increase in mortality.6,7  More recently, reduced HRV parameters have been reported as an 59 
independent predictor of 30-day mortality and provided additional predictive value over 60 
APACHE II scores in critically unwell patients.8  61 
 62 
The increased appreciation of the clinical potential of HRV analysis has led to its use in 63 
various clinical situations common to intensive care medicine including multiorgan 64 
dysfunction syndrome (MODS), sepsis and trauma.9,10,11 With this in mind, the following 65 
review aims to discuss the physiological basis of HRV, the measurement of HRV and the 66 
emerging clinical role of HRV analysis in intensive care medicine.  67 
 68 
Physiological basis of HRV 69 
 70 
Automaticity is common to cardiac pacemaker tissue however, heart rate and rhythm is 71 
continuously altered and regulated by the autonomic nervous system (ANS).12,2  72 
 73 
The parasympathetic nervous system (PNS) innervates the sinoatrial node, the 74 
atrioventricular node, and the atrial myocardium via the vagus nerve.13,1 Parasympathetic 75 
activation leads to release of acetylcholine (ACh) which slows the heart rate and lengthens 76 
the R-R interval.1,13 Parasympathetic activation leads to an almost immediate reduction in 77 
heart rate due to the very short latency of effect of ACh and the rate at which ACh is rapidly 78 
metabolised and cleared.1,2 Therefore the PNS regulates heart rate on a near beat by beat 79 
basis.1 In contrast, sympathetic nervous system (SNS) activation initiates the synaptic 80 
release of catecholamines, that increase cardiac contractility and heart rate.1,2 The action of 81 
catecholamines is slow compared to that of ACh and results in a delay between the onset of 82 
sympathetic stimulation and changes in heart rate of approximately 5 seconds.1,14 Despite 83 
the slower onset, sympathetic stimulation has a longer duration of action; affecting heart 84 
rate for 5-10 seconds following the cessation of a sympathetic stimulus.1,14  The differences 85 
in neurotransmitters between the PNS and SNS has led to the recognition that the effects of 86 
each arm of the ANS are not opposite and symmetrical but confer overlapping and different 87 
time frequencies of action.1 88 
 89 
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In healthy individuals’ cyclical changes in HRV occur with respiration and fluctuations in 90 
blood pressure.15,16   Frequency domain and power spectral density (PSD) analysis utilizes 91 
fast Fourier transform (FFT) analysis to describe oscillations in the RRi and transform them 92 
into discrete frequencies that help to conceptualise our understanding of the physiological 93 
mechanisms responsible for HRV.17,18 94 
 95 
Since cyclical changes in HRV are associated with respiration and occur at a high frequency 96 
(HF) of 0.25Hz they are thought to dominate a number of cardiorespiratory and neural 97 
interactions.16,2 These interactions are responsible for the observation of respiratory sinus 98 
arrhythmia (RSA), characterised by shortening of the RRi with inspiration and lengthening 99 
with expiration.1 Abolition of these high frequency oscillations can be achieved by 100 
parasympathetic blockade with atropine suggesting that they are parasympathetically 101 
mediated.15 102 
 103 
Cyclical changes associated with fluctuations in arterial blood pressure (ABP) occur at a low 104 
frequency (LF) of 0.10Hz and are thought to be mediated by the SNS.2 These oscillations 105 
occur in synchrony with arterial Mayer waves.1 Mayer waves are spontaneous oscillations in 106 
ABP whose amplitude is thought to measure sympathetic vasomotor tone.16 Mayer wave 107 
oscillations are thought to parallel oscillations in HRV and in particular the LF oscillations 108 
recognised in HRV.1 These are attenuated and completely abolished by alpha adrenergic 109 
antagonist drugs suggesting that sympathetic activity is important in the generation of these 110 
oscillations.1  There remains debate as to the precise physiological origin of Mayer waves in 111 
the generation of heart rate frequencies at 0.10Hz and controversy exists in attributing all LF 112 
HRV oscillations to sympathetic modulation.19 Research has demonstrated that 113 
parasympathetic blockade also produces modulation of low frequency oscillations in HRV.1 114 
Despite this, measurement of HF and LF oscillations calculated as a ratio of LF/HF has been 115 
suggested as a measure of sympathovagal balance with relative changes in the magnitude 116 
of each frequency reflecting the dominance of a particular arm of the ANS.2,15  117 
 118 
HF and LF components of HRV account for only 5% of the total power of HRV recordings 119 
measured by power spectral density analysis. The remaining 95% is accounted for by two 120 
other frequencies called the very-low frequency (VLF) band and ultra-low frequency (ULF) 121 
band.13 Historically these frequency components have not been well characterised. 122 
However, recent research suggests that the VLF band is associated with thermoregulatory 123 
mechanisms, changes in peripheral chemoreceptor activity and fluctuations in the renin-124 
angiotensin system (RAAS) whilst the ULF band is thought to reflect oscillations due to 125 
circadian rhythm.20,17 Despite relatively less being known about the VLF and ULF 126 
frequencies, they appear to be clinically important as reduced variability in the VLF band is 127 
associated with arrhythmias, high inflammation levels and increased mortality.21  128 
 129 
Measuring Heart Rate Variability 130 
 131 
In 1996 The European Society of Cardiology and the North American Society of Pacing and 132 
Electrophysiology published guidelines aimed at standardising the terminology and 133 
methodology used in the measurement of HRV.12 These guidelines describe a number of 134 
methods for measuring HRV including linear measures such as time domain and frequency 135 
domain measures and non-linear measures such as the Poincare plot.12 Recent advances in 136 
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biological systems theory, HRV analysis and complexity analysis have resulted in updated 137 
guidance for non-linear techniques such as entropy and fractal analysis that focus on 138 
similarities in the RRi over a given time period.20,22  139 
 140 
Time domain measures 141 
 142 
Time domain measures derive HRV using either statistical or geometric analysis.12 Statistical 143 
analyses (e.g. standard deviation) are applied to the RRi to measure variation over a 144 
specified period of time from <1min to 24 hours.12, 20 Geometric derivation of HRV requires 145 
that a series of RRi are converted into a geometric pattern, such as a sample density 146 
distribution of RRi and analysed using statistical methods (Table 1).12,23 147 
 148 
Time domain measures are easy to calculate and simple to derive.12,24 However, they are 149 
sensitive to artefact particularly supraventricular and ventricular extrasystolic beats.24 150 
Therefore, ECG recordings need careful pre-processing to ensure removal of extrasystolic 151 
beats and interference. Similarly, they require stationarity in the time series (i.e. the mean 152 
heart rate does not change significantly), which is a property not often met in biological 153 
systems.24 For these reasons time domain measures cannot discriminate between 154 
alterations in SNS or PNS output. Despite this, they can be used to assess overall ANS 155 
activity, and provide useful clinical information.1,24 156 
 157 
Frequency domain measures 158 
 159 
Frequency domain measures describe variation in the RRi following transformation into 160 
different frequency components. Frequency domain measures are derived using FFT 161 
analysis to provide information on the frequency components of HRV over a time series 162 
(Figure 1).2,12,24  In analysis of 2 to 5 minute ECG recordings three characteristic frequencies 163 
are recognised, LF, HF and VLF (Table 1).24 In 24 hour recordings the ULF band is recognised 164 
with the VLF band.12   In general, to accurately determine the power of a LF banding a 165 
recording greater or equal to approximately 5/f is required. Frequency domain, like time 166 
domain analysis, is sensitive to artefact, ectopic beats and require stationarity in the data 167 
series.24 Physiological mechanisms such as changes in posture, levels of stress and 168 
movement are thought to alter LF and HF readings, therefore, factors that are known to 169 
modulate the ANS should be controlled during HRV measurement.12, 24, 25    170 
 171 
Non-linear measures of HRV 172 
 173 
Non-linear measures overcome the requirement of stationarity in data unlike the linear 174 
measures.20,26 They include techniques such as the Poincare plot, detrended fluctuation 175 
analysis (DFA) and approximate and sample entropy analysis (ApEN and SampEN).26 Non-176 
linear measures model dynamic systems using variables that cannot be plotted on a straight 177 
line.22 Physiological systems are dynamic due to complex interactions between 178 
cardiovascular, endocrine and autonomic systems and do not ordinarily display stationarity. 179 
Therefore non-linear measures may offer a number of advantages over linear HRV measures 180 
when stationarity cannot be guaranteed.26  The non-linear methods implicitly assume that 181 
the factors that create HRV occur as oscillatory inputs with associated random variation.27   182 
Non-linear methods borrow techniques from fractal mathematics and produce variables 183 
 5 
that describe the pattern of variability by analysing temporal similarities in the signals.27 184 
Typically, parameters are derived that separately describe the scaling of short-term 185 
variability (e.g. <10 beats) and longer-term trends.  Whilst, as yet, these parameters do not 186 
offer a great deal of mechanistic insight, they are robust and can distinguish between 187 
patient groups.2   188 
 189 
Poincare plot 190 
 191 
Poincare plots are a graphical representation (scatter plot) of HRV generated by plotting 192 
each RRi against the prior RRi (Figure 2).20  193 
 194 
Poincare plots are analysed by fitting an ellipse to the data series. Three non-linear 195 
measures are typically derived, SD, SD1 and SD2 (Table 1).20 Total variability (S) in the 196 
sample is represented by the entire area of the ellipse.20  197 
 198 
Detrended fluctuation analysis 199 
 200 
DFA correlates the fluctuations between RRi over different time scales and analyses 201 
temporal self-similarities in the RRi.27 Short term fluctuations are represented by DFA1 202 
whilst long-term fluctuations are represented by DFA2.20 The calculation of DFA involves 203 
several steps and during the calculation, non-stationarity in the signal is addressed by 204 
subtraction of extrinsic fluctuations, this has been extensively reviewed elsewhere.28  The 205 
primary advantage of DFA is removal of confounding due to non-stationarity during DFA 206 
calculation.29 However it requires large data sets and whether it offers further information 207 
compared to other techniques requires further investigation.28,24 208 
 209 
Entropy  210 
 211 
Entropy analysis can be applied to a series of RRi and provides a measure of the degree of 212 
irregularity or “randomness” within the series24.   The technique essentially calculates the 213 
probability that any given sequence of intervals within the RRi series will be repeated.27 The 214 
more likely to be repeated the lower the calculated entropy. Measures of such entropy 215 
include the ApnEN and SampEN respectively.  Clinically, lower entropy values correlate to a 216 
state of illness24,30.  SampEN was introduced to address the sensitivity of ApnEN to sample 217 
size and the inaccuracy of ApnEN when the number of data points are low in a time series24.  218 
 219 
Factors affecting HRV measurement 220 
 221 
Despite the promising ability of HRV to provide information on biological systems there 222 
remains a number of physiological and technical issues that need to be considered when 223 
interpreting HRV clinically. The context of HRV recording is crucial, as numerous factors 224 
including age (increased age leads to reduced HRV), gender (higher HRV in females), resting 225 
heart rate and recent physical activity, are thought to alter HRV.20  Factors such as posture 226 
and movement also need to be considered as it has been shown that HRV is markedly 227 
altered between standing and supine positioning.12 HRV is also affected by a number of 228 
technical factors such as ECG sampling frequency, length of ECG recording and the presence 229 
of artefact or interference.12,20 To detect the R wave fiducial point on the ECG a sampling 230 
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frequency minimum of 500Hz is recommended.12 However as HRV decreases with illness it 231 
may be necessary to sample at a much higher frequency to ensure adequate resolution and 232 
accuracy.20 A recent systematic review of HRV use in critical care highlighted that a 233 
significant number of studies used sampling frequencies as low as 250Hz and these results 234 
should be considered with caution.11 Similarly, the length of recording is crucial and can 235 
significantly affect time and frequency domain HRV measures. Recommendations have been 236 
made regarding acceptable ECG recording lengths for each HRV measure, however the 237 
existing literature often fails to accurately report the duration of ECG recordings used in 238 
studies, potentially introducing an element of uncertainty to their results.11,12  Artefacts can 239 
significantly distort time and frequency domain HRV measures and the bias of a single 240 
artefact can distort the entire HRV recording. Manual inspection of ECG is recommended to 241 
ensure HRV analysis is conducted on ECG segments that are free of artefact, ectopic beats, 242 
missed beats and interference.12 Artefacts such as missed and ectopic beats can be resolved 243 
by artefact removal and interpolation of an R wave based on previous QRS intervals.20 244 
However, with increasing interpolation of R waves a significant amount of noise to signal 245 
ratio can be introduced in the data series and lead to errors in HRV measures. Similarly, 246 
arrhythmias such as atrial fibrillation (AF) can introduce significant distortion in HRV and 247 
therefore should not be considered accurate in patients with AF. These factors need to be 248 
considered when interpreting HRV in the clinical context.  249 
 250 
 251 
HRV in Intensive Care Medicine 252 
 253 
HRV is frequently used to describe the activity of the SNS and PNS. However, this relies on 254 
the assumption that the autonomic nervous system is in balance, with low PNS activity 255 
associated with a correspondingly high SNS activity and vice versa.31 Many authors have 256 
refuted this, and it is generally accepted that the relative balance of the ANS is more 257 
complex.  258 
 259 
Similarly, mechanisms responsible for RRi and HRV are complex and reflect inputs from 260 
multiple physiological systems, including the SNS, PNS, renin-angiotensin system, 261 
thermoregulatory systems, as well as mechanical inputs from respiration and alterations in 262 
arterial blood pressure.32  263 
 264 
Despite debate regarding the association between HRV and the ANS, the previous two 265 
decades have witnessed a significant expansion in the use of HRV analysis and increasing 266 
evidence supporting its use in critical care.11  267 
 268 
Autonomic dysfunction is common to a number of disorders seen in critical care patients, 269 
such as MODS, sepsis, myocardial infarction, decompensated heart failure and  severe brain 270 
injury (SBI).11,33,34  The ability to assess autonomic function may provide valuable 271 
information regarding the pathophysiology, severity and prognosis of these disorders.33 272 
However the reader is reminded that whilst an association between HRV and the ANS 273 
certainly exists, HRV does not directly measure autonomic activity and any association is 274 
likely a combination of complex physiological inputs.31 With this in mind the remainder of 275 
this review will focus on areas in which HRV has found utility in intensive care medicine.  276 
 277 
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Multiple organ dysfunction syndrome and Sepsis 278 
 279 
As early as 1995 it was recognised that SDNN, LF, LF/HF are reduced in sepsis.11,35, 36,37 Godin 280 
and Buchman suggested that organ systems are connected to each other via neural, 281 
hormonal and cytokine networks and that they each behave as biological oscillators.38 They 282 
hypothesised that sepsis resulted in an uncoupling of organ systems and leads to a 283 
reduction in HRV parameters.38,30 They proposed that HRV was a method for the 284 
quantification of ‘inter-organ communication’ and yielded valuable information in the 285 
pathophysiology of sepsis and prognosis of patients admitted to the intensive care unit 286 
(ITU).38 Recently, Bishop et al reported that reduction in the VLF domain was predictive of 287 
30 day all-cause mortality in patients admitted to ITU.39 Similar findings have been reported 288 
by Schmidt who found that a reduced VLF was predictive of 28 day mortality in patients with 289 
MODS.40 HRV analysis may be able to predict mortality early in a patient’s presentation, 290 
with Chen reporting that a reduced SDNN was predictive of in-hospital mortality in septic 291 
patients admitted to the accident and emergency department.9 Interestingly, Chen also 292 
reported that an increased HF was predictive of hospital survival, suggesting that health is 293 
associated with a high degree of variability.9  This was confirmed by Papaioannou in a novel 294 
study that tracked changing HRV in response to a patient’s pathophysiological state.41 SOFA 295 
scores were longitudinally tracked with a number of HRV measures over time and revealed 296 
that entropy was reduced in non-survivors, and the long term non-linear HRV parameter 297 
DFA2 correlated with length of ITU stay.41 Moreover, patients that were more clinically 298 
unstable had a reduced LF/HF ratio, and a reduction in overall variance.41 This recovered as 299 
patients improved and were finally discharged from critically care, suggesting that HRV 300 
analysis may be valuable as a method of monitoring physiological deterioration and offer 301 
real time prognostication in critically unwell patients.41   302 
 303 
HRV may also serve to predict those patients at risk of deterioration and those who may 304 
benefit from early ITU admission. In a recent observational study in septic emergency 305 
department patients, Samsudin et al report a scoring system utilising two vital signs 306 
(respiratory rate and systolic blood pressure), age and two HRV measures (mean RRi and 307 
DFA2).42 They revealed that the use of HRV not only outperformed SOFA, NEWS and 308 
MEWS scoring at prediction of 30 day mortality but, was also able to accurately predict 309 
those patients requiring ITU admission and intubation.42 Similar scoring systems utilising 310 
HRV have already shown promise in neonatal patients. In the landmark HeRO Trial, 311 
Moorman et al revealed that monitoring heart rate characteristics including reduced 312 
variability and transient heart rate decelerations, led to a 22% relative reduction in mortality 313 
in very low birthweight neonates.43 The HeRO trial provided clinicians with a score based 314 
upon a composite measure utilising SD RRi, sample asymmetry (a measure of transient 315 
accelerations and deceleration of the heart rate) and SampEN.44 Using multivariable logistic 316 
regression and mathematical algorithms, the HeRO score provides continuous non-invasive 317 
monitoring that estimates the fold-increase in the probability of sepsis.44,43  The HeRO trial 318 
and scoring systems developed by Samsudin hint at the possibility of a new generation of 319 
physiomarkers for the earlier detection of deterioration and sepsis.42,44 320 
 321 
HRV and inflammation 322 
 323 
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Inflammation is associated with a number of conditions that present to ITU such as 324 
myocardial infarction, sepsis, systemic inflammatory response syndrome, MODs and severe 325 
trauma.45 Factors that trigger inflammation also enhance anti-inflammatory pathways that 326 
counterbalance the initial pro-inflammatory signal.45, 21 An inflammatory reflex has been 327 
described in which cytokines induce neuroendocrine modulatory mechanisms that signal via 328 
the autonomic nervous system.21,45  In response to inflammation vagal outflow increased 329 
systemically and more specifically to organs such as the spleen that are thought to be 330 
responsible for the upregulation of anti-inflammatory cytokine levels.45,46 It is thought that 331 
this counter-regulatory mechanism confers protection against unregulated tissue damage in 332 
inflammatory conditions and poly-microbial infection and is known as the ‘cholinergic anti-333 
inflammatory pathway.’45 HRV analysis has helped elucidate the role the ANS plays in the 334 
inflammatory reflex, and a depressed parasympathetic activity has been implicated in the 335 
pathogenesis of diseases associated with an exaggerated inflammatory response.45 A 336 
number of authors have correlated HRV with inflammatory markers.21,47,48 Tateishi 337 
investigated the relationship between IL-6 and HRV in patients admitted to critical care with 338 
sepsis and found that IL-6 was negatively correlated with the LF component of HRV 339 
analysis.47 Papaioannou tracked patients from admission to critical care and reported an 340 
inverse correlation between LF and LF/HF and C-reactive protein (CRP) levels.21  HF HRV was 341 
correlated with IL-10 levels, suggesting that LF/HF ratio and reduced LF HRV is related to 342 
both pro-inflammatory and anti-inflammatory responses.21 Furthermore, those patients 343 
that developed shock had increased biomarkers (CRP, IL-6, IL-10) and decreased HRV, 344 
reaching statistical significance in patients with a SOFA score >10.21 This suggests that HRV is 345 
related to both anti-inflammatory and pro-inflammatory signals with a stronger association 346 
being present in patients that are more unwell.21  347 
 348 
There is strong evidence that the ANS influences the physiological response to inflammation 349 
and recent research suggests that the anticholinergic anti-inflammatory pathway may hold 350 
promise as a therapeutic target.21,49 HRV measurement may therefore prove to be a novel 351 
physiomarker that characterises the cardiorespiratory responses to inflammation and may 352 
have prognostic value in any future anti-inflammatory treatments.50 353 
 354 
Cardiovascular disorders, arrhythmias and cardiac arrest 355 
 356 
It is generally accepted that HRV is a powerful predictor of cardiac mortality, arrhythmia and 357 
sudden cardiac death, and is independent of other risk factors (left ventricular ejection 358 
fraction, ventricular extra-systoles and episodes of non-sustained ventricular tachycardia) 359 
after myocardial infarction.5,7,12,51  A substudy of the large ATRAMI trial found that 360 
decreased SDNN and impaired heart rate response to an increase in blood pressure 361 
(baroreceptor sensitivity) were predictors of cardiac mortality.52 In patients with a reduced 362 
ejection fraction, the presence of a reduced SDNN or low baroreceptor sensitivity carried a 363 
relative risk of mortality of  6.7 and 8.7 respectively.52 Reduced HRV may also provide an 364 
early warning of deterioration as Passariello et al has shown that patients who suffer 365 
sudden cardiac death secondary to fatal arrhythmia have a marked decrease in SDNN in the 366 
five minutes preceding its onset.53 Similar findings are reported in patients that suffer from 367 
paroxysmal AF, where ApnEN was decreased up to 100 minutes prior to the onset of 368 
arrhythmia.22 That HRV analysis appears to be able to predict patients at risk of cardiac 369 
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mortality and arrhythmias may prove useful for risk stratification, particularly in patients at 370 
increased cardiovascular risk such as in the peri-operative period.33  371 
 372 
HRV has also been used to monitor the responses to drug treatment in patients with 373 
cardiovascular disease and hypertension. Beta-antagonists such as metoprolol and atenolol 374 
tend to augment HF whilst reducing LF in patients with hypertension.54 Similar findings have 375 
been reported post myocardial infarction, were the addition of metoprolol lead to a 376 
reduction in LF output.54 However, cardiovascular drugs such as, statins and calcium channel 377 
antagonists have been found to have a variable effect on HRV.11 Interestingly drugs that 378 
would be expected to have profound effects on the ANS such as catecholamines have also 379 
been shown to have variable effects on HRV. A recent systematic review reported three 380 
studies that did not show any association between HRV parameters and vasopressor 381 
requirement or administration of exogenous catecholamines.11 Despite no finding of an 382 
association the authors highlighted that the majority of studies failed to report the 383 
administration of cardiovascular drugs, vasopressors or catecholamines and had limited 384 
ability to draw any conclusions regarding the potential effects on HRV.11,54 385 
  386 
HRV may also offer important information regarding neurological recovery post cardiac 387 
arrest.33,55 Tiainen et al in a randomised trial reported significantly higher HRV measures in 388 
those patients that underwent therapeutic hypothermia (TH) compared to normothermia 389 
post cardiac arrest.55 Higher SDNN, SDANN, HF and LF measures were recorded in the first 390 
48 hours of TH.55 The authors suggest that higher HRV measures may represent a beneficial 391 
effect on myocardial function and preservation of ANS function or the neuroprotective 392 
effects of cooling.55 However, they acknowledge that this finding may be due to 393 
confounding and secondary to the relative bradycardia that TH induces in patients.55 The 394 
exact mechanism underlying improved HRV with TH remains uncertain, despite this the 395 
potential of HRV to predict outcome post cardiac arrest should be confirmed with larger 396 
trials.33,55 397 
 398 
Neurological disorders 399 
 400 
Lowhenshon was amongst the first authors to investigate the links between HRV and 401 
neurological disorders.56 In brain-damaged adults Lowhenshon revealed that HRV decreased 402 
and rapidly diminished in line with increases in intracranial pressure (ICP).56 A more recent 403 
study in 145 trauma patients confirmed that an increase in intracranial pressure, as 404 
measured by invasive intracranial pressure monitoring, is preceded by a reduction in heart 405 
rate variability.57 Reduction in HRV has been shown to be proportional to the increase in 406 
intracranial pressure, with more marked alterations in HRV occurring when ICP was 407 
>30mmHg or cerebral perfusion pressure <40mmHg.33 Moreover, reductions in HRV 408 
preceded changes in ICP by approximately 24 hours.57 These findings suggest that HRV may 409 
function as a non-invasive method of monitoring early changes in intracranial pressure and 410 
may identify those patients that would benefit from invasive monitoring.57  411 
 412 
Complications following subarachnoid haemorrhage (SAH) can include severe vasospasm, 413 
neurogenic stress cardiomyopathy, and cardiac arrhythmias.58 Reduction in RMSSD has 414 
been shown to be associated with neurogenic stress cardiomyopathy following SAH.58 415 
Similar alterations in HRV have been recognised in extradural, subdural, and intracerebral 416 
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haematomas.33 Schmidt et al have investigated VLF reductions and delayed cerebral 417 
ischaemia secondary to cerebral vasospasm in SAH patients.59 It is thought that VLF may 418 
partly represent parasympathetic outflow and reductions in VLF are associated with states 419 
of high inflammation.20 Both RMSSD and VLF have been shown to predict complications 420 
following SAH, and it has been suggested that this may be related to the pro-inflammatory 421 
response contributing to the development of cerebral ischaemia after SAH.59   422 
 423 
Changes in HRV have also been shown to be an early indication of the occurrence of brain 424 
death.60 Conci reported a reduction in the total power of frequency domain analysis and 425 
suggested that these changes likely mirror a cessation of the activity of cardiorespiratory 426 
brainstem centres.60 These findings have been confirmed by others who measured 427 
continuous HRV and found that the loss of spectral power occurred during the transition to 428 
brain death.61 Taken together these findings may be useful as a complementary method in 429 
the diagnosis of brain stem death and help inform when more formal brain stem death 430 
testing should occur.60,61  431 
 432 
 433 
Conclusion  434 
 435 
HRV analysis offers a unique monitoring modality that provides information regarding 436 
variability in complex biological signals. Unlike existing monitoring, HRV can potentially 437 
detect and track the state of the whole physiological system over time and during the 438 
development of illness, potentially even before it is clinically apparent. Goldberger 439 
described illness as the de-complexification of complex biological systems and suggested 440 
that health is characterised by ‘organised variability’ whilst reduced variability is associated 441 
with disease states, such as multi-organ dysfunction syndrome and sepsis.62 The inclusion of 442 
HRV measures into current early warning scoring systems such as NEWS could potentially 443 
lead to a new generation of physiomarkers that can predict deterioration earlier and help 444 
target those patients at greatest risk of mortality.42 The HeRO trial and HeRO monitoring 445 
system has shown that incorporation of HRV measures can potentially lead to earlier 446 
investigation and treatment and significantly improved clinical outcomes.44   447 
 448 
Despite the potential of HRV measurement, it is still largely a research technique and has 449 
not become part of routine monitoring in critical care.63 There are a number of potential 450 
reasons for this. First, despite the large number of experimental studies, the majority are 451 
cohort or case-control studies of low methodological quality.11 Many studies also failed to 452 
fully account for confounding factors such as commonly used drugs in ITU  including anti-453 
arrhythmic medications and the impact that interventions in ITU such as mechanical 454 
ventilation have on HRV parameters.11 Second, there is a lack of standardised methodology 455 
for the recording, processing and derivation of HRV from ECG. Despite guidelines from The 456 
European Society of Cardiology and the North American Society of Pacing and 457 
Electrophysiology, obtaining clinically useful HRV parameters still requires clinicians to pre-458 
process ECG and RRi data using standard ECG monitoring equipment before using 459 
standalone software to derive HRV parameters.12 A number of open source software 460 
packages written in Matlab mathematical language are available as well as a number of paid 461 
software packages such as  Kubios and ARTiiFACT.64,65,66 To date the authors are not aware 462 
of any monitoring systems that derive HRV in real-time at the bedside and this likely limits 463 
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its widespread use in ITU. Third, despite evidence to suggest that HRV can predict 464 
deterioration, arrhythmias and MODS, the exact pathophysiological mechanisms underlying 465 
these associations remains unclear. Throughout this review we have discussed HRV as a 466 
measure of autonomic function. In reality individual HRV parameters are more complex and 467 
multiple physiological factors impact upon them.31 Until the exact mechanisms responsible 468 
for measured HRV parameters are uncovered it is difficult to fully define a mechanistic basis 469 
for HRV.31 470 
 471 
Measurement of HRV, along with advances in biomedical engineering and computational 472 
methods, has increased our understanding of the role the ANS plays in the pathophysiology 473 
of disease and illness. But for HRV analysis to become a standard of monitoring in critical 474 
care, prospective studies are needed to address the technical considerations, determine 475 
what factors confound HRV analysis, and develop consensus standards for HRV monitoring 476 
in critical care. In conclusion if these challenges are addressed, HRV analysis has the 477 
potential to revolutionise critical care monitoring and introduce an era of monitoring based 478 
upon individualised variability analysis. 479 
  480 
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